Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Why Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients Need Passive Immunity

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

CLL Society’s Executive VP and Chief Medical Officer (CMO), Dr. Brian Koffman has been busy over the last weeks trying to get the word out about the unique risks and needs of the CLL/SLL community on TV, news, and medical literature as listed below.

  1. ABC TV News interview: In-Depth: FDA weighs new COVID antibody drug that could be ‘holy grail’ for immunocompromised
  2. Washington Post letter to the editor: Opinion: Why we need passive immunity

And in case you missed it:

  1. JAMA (Journal of the American Medical Association) Oct. 27, 2021, report: Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis Can’t Come Fast Enough for Some People

More interviews and articles to come. CLL Society is trying to raise awareness about both how chronic lymphocytic leukemia/small lymphocytic lymphoma patients remain vulnerable to COVID-19 and about the benefits of prophylaxis with anti-SARS-CoV-2 monoclonal antibodies.